Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Nephrology · Membranoproliferative Glomerulonephritis

Biology and Secondary Causes: Getting the Right Diagnosis

At a Glance

Primary MPGN is considered a diagnosis of exclusion. Before treating the condition, doctors must thoroughly test for secondary causes like chronic infections, autoimmune diseases, or MGRS. Treating the kidney without addressing the true underlying cause will not stop the damage.

To understand MPGN (Membranoproliferative Glomerulonephritis), you must first understand the complement system. This is a powerful part of your immune system designed to “complement” your antibodies by attacking invaders like bacteria and viruses. However, in MPGN and C3G, this system becomes overactive, mistakenly attacking the tiny filters in your kidneys [1][2].

The Two Pathways of Injury

The complement system can be triggered in different ways, which helps doctors distinguish between IC-MPGN and C3G [3][4]:

  • The Classical Pathway (IC-MPGN): This pathway is usually triggered when antibodies latch onto a target (like a virus or a self-antigen). In IC-MPGN, both these immune complexes (antibody-target pairs) and complement proteins are found in the kidney [1][5].
  • The Alternative Pathway (C3G): This part of the immune system is always “on” at a low level, like a pilot light. In C3G, the “off switch” for this pathway is broken, causing it to flare up and damage the kidney directly without needing antibodies to trigger it [3][2].

Regardless of which pathway starts the fire, they both lead to a final, destructive phase (the terminal pathway) that causes inflammation and scarring in the kidney [6][2].

Why “Primary” is a Diagnosis of Exclusion

Before a doctor can call your condition primary (or idiopathic), they must perform a deep investigation to ensure something else isn’t causing the kidney damage [5][7]. Treating primary MPGN when it is actually secondary—meaning it is caused by an underlying condition—is like trying to put out a fire without turning off the gas line. If the underlying cause isn’t treated, the kidney damage will continue [8][9].

Major Secondary Causes

The most common conditions that can create an MPGN pattern include:

  • Chronic Infections: Hepatitis C is a leading cause, often through a condition called cryoglobulinemia (where proteins in the blood clump together in the cold). Hepatitis B, HIV, and certain bacterial infections can also be triggers [10][8][11].
  • Autoimmune Diseases: Conditions like Systemic Lupus Erythematosus (SLE) can cause the immune system to create the “immune complexes” that lead to the MPGN pattern [12][5].
  • MGRS (Monoclonal Gammopathy of Renal Significance): This is a critical condition where a small, “quiet” group of cells in the bone marrow produces an abnormal protein that damages the kidney [13][14].

The Importance of Ruling Out MGRS

MGRS is frequently confused with primary MPGN because the abnormal protein can be very difficult to detect [15][16]. However, the distinction is vital:

  1. Different Treatments: MGRS requires therapies that target those specific bone marrow cells, rather than general immune-suppressing drugs [15][17].
  2. Hidden Deposits: Sometimes these abnormal proteins are “masked” or hidden on a standard biopsy. Specialized tests, such as pronase digestion or paraffin immunofluorescence, may be needed to uncover them [18][19].

Ensuring your doctor has performed a full “secondary workup”—including blood tests for hepatitis, autoimmune markers, and protein electrophoresis—is the best way to ensure you receive the correct treatment for your specific situation [20][21][22].

Return to Home

Common questions in this guide

What is the difference between IC-MPGN and C3G?
IC-MPGN is triggered when antibodies attach to a target and activate the classical complement pathway. C3G happens when the alternative pathway's 'off switch' breaks, damaging the kidney without needing antibodies. Both cause inflammation and scarring in the kidneys.
Why is primary MPGN called a diagnosis of exclusion?
Doctors can only diagnose primary MPGN after they have completely ruled out all other underlying conditions. If the kidney damage is caused by an infection, autoimmune disease, or hidden protein, it is considered secondary MPGN and requires different treatment.
What are the most common secondary causes of MPGN?
Common secondary triggers include chronic infections like Hepatitis C, autoimmune diseases like Systemic Lupus Erythematosus (SLE), and Monoclonal Gammopathy of Renal Significance (MGRS). Identifying these is critical because each requires a different treatment approach.
Why is testing for MGRS so important if I have MPGN?
MGRS is caused by abnormal proteins from bone marrow cells that damage the kidneys, and it requires specific targeted therapies rather than general immune suppressants. These proteins can be hidden on standard biopsies, so specialized tests may be needed to find them.
What is the complement system's role in MPGN?
The complement system is a powerful part of your immune system designed to attack invaders like viruses and bacteria. In MPGN, this system becomes overactive and mistakenly attacks the tiny filters in your kidneys, leading to inflammation.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my biopsy, is there evidence of classical pathway activation (like C1q or C4 staining) or just the alternative pathway?
  2. 2.Have we ruled out common viral triggers like Hepatitis C and B, and have I been tested for HIV?
  3. 3.Could my 'primary' diagnosis actually be an autoimmune condition like Lupus or cryoglobulinemia?
  4. 4.Given the risk of MGRS, did the pathology lab use special techniques like 'pronase digestion' to look for hidden proteins?
  5. 5.Is it possible that my MPGN is a symptom of a small, hidden clone of cells in my bone marrow?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (22)
  1. 1

    De novo glomerular diseases after renal transplantation: How is it different from recurrent glomerular diseases?

    Abbas F, El Kossi M, Jin JK, et al.

    World journal of transplantation 2017; (7(6)):285-300 doi:10.5500/wjt.v7.i6.285.

    PMID: 29312858
  2. 2

    Functional Characterization of Anti-C3bBb Autoantibodies and C3 Glomerulopathy Phenotype.

    Roquigny J, Meuleman MS, El Sissy C, et al.

    Journal of the American Society of Nephrology : JASN 2025; (36(2)):264-273 doi:10.1681/ASN.0000000000000499.

    PMID: 39325562
  3. 3

    Mycophenolate Mofetil Treatment of C3 Glomerulopathy.

    Peleg Y, Appel GB

    Clinical journal of the American Society of Nephrology : CJASN 2020; (15(9)):1234-1236 doi:10.2215/CJN.11740720.

    PMID: 32841154
  4. 4

    Diagnostic Challenges and Emerging Pathogeneses of Selected Glomerulopathies.

    Andeen NK, Hou J

    Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society 2024; (27(5)):387-410 doi:10.1177/10935266241237656.

    PMID: 38576387
  5. 5

    Expert Discussion on Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Challenges and Considerations.

    Lafayette RA, Charu V, Glassock RJ

    Advances in therapy 2025; (42(5)):2003-2014 doi:10.1007/s12325-025-03167-x.

    PMID: 40146368
  6. 6

    Complement Terminal Pathway Activation and Intrarenal Immune Response in C3 Glomerulopathy.

    Meuleman MS, Petitprez F, Pickering MC, et al.

    Journal of the American Society of Nephrology : JASN 2024; (35(8)):1034-1044 doi:10.1681/ASN.0000000000000373.

    PMID: 38709564
  7. 7

    Membranoproliferative glomerulonephritis in Russian population.

    Dobronravov VA, Smirnov AV

    Terapevticheskii arkhiv 2018; (90(12)):39-47 doi:10.26442/00403660.2018.12.000007.

    PMID: 30701832
  8. 8

    A case of rapid amelioration of hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis treated by interferon-free directly acting antivirals for HCV in the absence of immunosuppressant.

    Obata F, Murakami T, Miyagi J, et al.

    CEN case reports 2017; (6(1)):55-60 doi:10.1007/s13730-016-0244-z.

    PMID: 28509128
  9. 9

    Immune Thrombocytopenic Purpura Complicated by Hepatitis C Virus-related Membranoproliferative Glomerulonephritis after Rituximab Therapy.

    Kubodera A, Kume A, Hayashi K, et al.

    Internal medicine (Tokyo, Japan) 2021; (60(15)):2469-2473 doi:10.2169/internalmedicine.6758-20.

    PMID: 33583904
  10. 10

    Clinical and pathological considerations on renal diseases in patients with chronic viral hepatitis.

    Iovănescu VF, Constantinescu AF, Streba CT, et al.

    Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie 2016; (57(2)):401-6.

    PMID: 27516011
  11. 11

    Membranoproliferative Glomerulonephritis Associated with a Human Immunodeficiency Virus Infection.

    Rafik H, El Amrani M, El Kabbaj D

    Indian journal of nephrology 2017; (27(4)):319-320 doi:10.4103/0971-4065.202838.

    PMID: 28761237
  12. 12

    Renal interstitial mast cell count is significantly higher in membranoproliferative glomerulonephritis than in class IV lupus nephritis.

    Kaczmarczyk K, Musiał J, Soja J, et al.

    Polish journal of pathology : official journal of the Polish Society of Pathologists 2015; (66(2)):149-53 doi:10.5114/pjp.2015.53011.

    PMID: 26247528
  13. 13

    Renal manifestations of MGUS.

    Bridoux F, Nasr SH, Arnulf B, et al.

    Hematology. American Society of Hematology. Education Program 2024; (2024(1)):489-498 doi:10.1182/hematology.2024000573.

    PMID: 39644070
  14. 14

    Monoclonal gammopathy of renal significance: Early diagnosis is key.

    Alonso-Titos J, Martínez-Esteban MD, López V, et al.

    Nefrologia 2021; (41(5)):502-513 doi:10.1016/j.nefroe.2021.11.008.

    PMID: 36165133
  15. 15

    Successful Renal Outcome in Membranoproliferative Glomerulonephritis Following Treatment of the Underlying Subtle Clone: A Case Report.

    Rana R, Cockwell P, Vydianath B, et al.

    Mayo Clinic proceedings. Innovations, quality & outcomes 2018; (2(3)):297-302 doi:10.1016/j.mayocpiqo.2018.04.003.

    PMID: 30225464
  16. 16

    C3 glomerulonephritis associated with monoclonal gammopathy of renal significance: case report.

    Alonso-Titos J, Perea-Ortega L, Sola E, et al.

    BMC nephrology 2018; (19(1)):129 doi:10.1186/s12882-018-0927-0.

    PMID: 29884135
  17. 17

    A rare case of MGRS with immunotactoid glomerulopathy responding to bortezomib, dexamethasone, and rituximab.

    Kuang C, Quann K, Liman AK, et al.

    Clinical case reports 2020; (8(10)):1984-1987 doi:10.1002/ccr3.3044.

    PMID: 33088534
  18. 18

    Membranoproliferative glomerulonephritis with masked monotypic immunoglobulin deposits.

    Larsen CP, Messias NC, Walker PD, et al.

    Kidney international 2015; (88(4)):867-73 doi:10.1038/ki.2015.195.

    PMID: 26154922
  19. 19

    Immunohistochemistry May Not Replace Immunofluorescence in Paraffin-embedded Tissue for Detecting Masked Monoclonal Immunoglobulin Deposits.

    Oda Y, Ikeda Y, Abe H, et al.

    Internal medicine (Tokyo, Japan) 2023; (62(24)):3657-3661 doi:10.2169/internalmedicine.1117-22.

    PMID: 37121755
  20. 20

    [Modern approaches to the detection of monoclonal gammopathy of undetermined significance (MGUS) in patients with kidney diseases].

    Kozlovskaya Lysenko LV, Chebotareva NV, Mrykhin NN, et al.

    Terapevticheskii arkhiv 2019; (91(6)):67-72 doi:10.26442/00403660.2019.06.000281.

    PMID: 36471598
  21. 21

    [Diagnosis and treatment of kidney involvement in plasma cell diseases : Renal involvement in multiple myeloma and monoclonal gammopathies].

    Gödecke V, Schmidt JJ, Bräsen JH, et al.

    Der Internist 2019; (60(1)):10-22 doi:10.1007/s00108-018-0538-7.

    PMID: 30635666
  22. 22

    Repeated Kidney Biopsy in Membranoproliferative Glomerulonephritis.

    Li AH, Li Y, Li MS, et al.

    Kidney diseases (Basel, Switzerland) 2025; (11(1)):258-269 doi:10.1159/000545727.

    PMID: 40337160

This page explains the biology and potential secondary causes of MPGN for educational purposes only. Always consult your nephrologist for an accurate diagnosis and personalized treatment plan.

Get notified when new evidence is published on Primary membranoproliferative glomerulonephritis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.